CY1125273T1 - Ανταγωνιστης υποδοχεα glp-1 για χρηση στη θεραπεια συγγενους υπερινσουλινισμου - Google Patents
Ανταγωνιστης υποδοχεα glp-1 για χρηση στη θεραπεια συγγενους υπερινσουλινισμουInfo
- Publication number
- CY1125273T1 CY1125273T1 CY20221100188T CY221100188T CY1125273T1 CY 1125273 T1 CY1125273 T1 CY 1125273T1 CY 20221100188 T CY20221100188 T CY 20221100188T CY 221100188 T CY221100188 T CY 221100188T CY 1125273 T1 CY1125273 T1 CY 1125273T1
- Authority
- CY
- Cyprus
- Prior art keywords
- glp
- treatment
- receptor antagonist
- congenital hyperinsulinism
- hyperinsulinism
- Prior art date
Links
- 208000000454 Congenital Hyperinsulinism Diseases 0.000 title abstract 2
- 208000033442 familial 1 hyperinsulinemic hypoglycemia Diseases 0.000 title abstract 2
- 208000033961 familial 2 hyperinsulinemic hypoglycemia Diseases 0.000 title abstract 2
- 208000011532 familial hyperinsulinism Diseases 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 title 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- WSEVKKHALHSUMB-RYVRVIGHSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O WSEVKKHALHSUMB-RYVRVIGHSA-N 0.000 abstract 1
- 108010024703 exendin (9-39) Proteins 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Ένας ανταγωνιστής του υποδοχέα Πεπτιδίου-1 που Μοιάζει με Γλυκαγόνη (GLP-1), ή μία σύνθεση εξενδίνης-(9-39), για χρήση στη θεραπεία συγγενούς υπερινσουλινισμού.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87903307P | 2007-01-08 | 2007-01-08 | |
| EP08713063.9A EP2120994B1 (en) | 2007-01-08 | 2008-01-08 | Methods and compositions for treating hypoglycemic disorders |
| PCT/US2008/000281 WO2008085982A2 (en) | 2007-01-08 | 2008-01-08 | Methods and compositions for treating hypoglycemic disorders |
| EP14171762.9A EP2818181B1 (en) | 2007-01-08 | 2008-01-08 | Compositions and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125273T1 true CY1125273T1 (el) | 2023-06-09 |
Family
ID=39609282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100188T CY1125273T1 (el) | 2007-01-08 | 2022-03-04 | Ανταγωνιστης υποδοχεα glp-1 για χρηση στη θεραπεια συγγενους υπερινσουλινισμου |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9821031B2 (el) |
| EP (4) | EP4049673A1 (el) |
| CY (1) | CY1125273T1 (el) |
| DK (1) | DK3456340T3 (el) |
| ES (3) | ES2499390T3 (el) |
| HR (1) | HRP20220346T3 (el) |
| HU (1) | HUE058307T2 (el) |
| LT (1) | LT3456340T (el) |
| PL (1) | PL3456340T3 (el) |
| PT (1) | PT3456340T (el) |
| SI (1) | SI3456340T1 (el) |
| TR (1) | TR201900959T4 (el) |
| WO (1) | WO2008085982A2 (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2499390T3 (es) | 2007-01-08 | 2014-09-29 | The Trustees Of The University Of Pennsylvania | Métodos y composiciones para tratar trastornos hipoglucémicos |
| EP2817025A2 (en) * | 2012-02-08 | 2014-12-31 | Seneb Biosciences, Inc. | Treatment of hypoglycemia |
| US10077319B2 (en) * | 2014-02-21 | 2018-09-18 | Medimmune, Llc | Anti-PCSK9-GLP-1 fusions and methods for use |
| US10711067B2 (en) | 2015-03-03 | 2020-07-14 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
| EP3978011A1 (en) | 2015-05-22 | 2022-04-06 | The Board of Trustees of the Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with glp-1 antagonists |
| WO2017152014A1 (en) | 2016-03-04 | 2017-09-08 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
| JP2019535734A (ja) | 2016-11-21 | 2019-12-12 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | エキセンディン（９−３９）の緩衝製剤 |
| CN116606367A (zh) * | 2022-05-31 | 2023-08-18 | 南京盛德瑞尔医药科技有限公司 | 长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US20040092443A1 (en) * | 1996-08-06 | 2004-05-13 | Yeda Research And Development Co., Ltd | Long-acting exendins and exendin agonists |
| PT1137413E (pt) * | 1998-12-10 | 2005-05-31 | Agouron Pharma | Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao |
| US6903074B1 (en) | 1999-06-04 | 2005-06-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Neuromedin b and somatostatin receptor agonists |
| SE0004462D0 (sv) * | 2000-12-04 | 2000-12-04 | Pharmacia Ab | Novel method and use |
| WO2002066062A2 (en) * | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
| US7638598B2 (en) | 2001-04-06 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | ErbB interface peptidomimetics and methods of use thereof |
| CN1162446C (zh) * | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
| US7378385B2 (en) | 2002-08-08 | 2008-05-27 | University Of Cincinnati | Role for GLP-1 to mediate responses to disparate stressors |
| DE102004043153B4 (de) | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
| MX2008015107A (es) | 2006-05-26 | 2008-12-09 | Amylin Pharmaceuticals Inc | Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva. |
| ES2499390T3 (es) * | 2007-01-08 | 2014-09-29 | The Trustees Of The University Of Pennsylvania | Métodos y composiciones para tratar trastornos hipoglucémicos |
| DK2310042T3 (da) | 2008-07-08 | 2013-03-04 | Novartis Ag | Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi |
| PT2440228T (pt) | 2009-06-08 | 2018-12-24 | Amunix Operating Inc | Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| EP3978011A1 (en) | 2015-05-22 | 2022-04-06 | The Board of Trustees of the Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with glp-1 antagonists |
| JP2019535734A (ja) | 2016-11-21 | 2019-12-12 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | エキセンディン（９−３９）の緩衝製剤 |
-
2008
- 2008-01-08 ES ES08713063.9T patent/ES2499390T3/es active Active
- 2008-01-08 EP EP22156122.8A patent/EP4049673A1/en active Pending
- 2008-01-08 US US12/522,274 patent/US9821031B2/en active Active
- 2008-01-08 LT LTEP18201976.0T patent/LT3456340T/lt unknown
- 2008-01-08 HU HUE18201976A patent/HUE058307T2/hu unknown
- 2008-01-08 HR HRP20220346TT patent/HRP20220346T3/hr unknown
- 2008-01-08 SI SI200832192T patent/SI3456340T1/sl unknown
- 2008-01-08 PL PL18201976.0T patent/PL3456340T3/pl unknown
- 2008-01-08 TR TR2019/00959T patent/TR201900959T4/tr unknown
- 2008-01-08 ES ES14171762T patent/ES2710948T3/es active Active
- 2008-01-08 EP EP14171762.9A patent/EP2818181B1/en active Active
- 2008-01-08 EP EP18201976.0A patent/EP3456340B1/en active Active
- 2008-01-08 PT PT182019760T patent/PT3456340T/pt unknown
- 2008-01-08 EP EP08713063.9A patent/EP2120994B1/en active Active
- 2008-01-08 ES ES18201976T patent/ES2908838T3/es active Active
- 2008-01-08 WO PCT/US2008/000281 patent/WO2008085982A2/en active Application Filing
- 2008-01-08 DK DK18201976.0T patent/DK3456340T3/da active
- 2008-04-10 US US12/081,123 patent/US9616108B2/en active Active
-
2017
- 2017-03-08 US US15/453,823 patent/US10188702B2/en active Active
-
2019
- 2019-01-28 US US16/258,686 patent/US10987407B2/en active Active
-
2020
- 2020-11-25 US US17/105,484 patent/US20210252110A1/en not_active Abandoned
-
2022
- 2022-03-04 CY CY20221100188T patent/CY1125273T1/el unknown
-
2023
- 2023-02-14 US US18/168,570 patent/US20240082361A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2818181A1 (en) | 2014-12-31 |
| US9821031B2 (en) | 2017-11-21 |
| TR201900959T4 (tr) | 2019-02-21 |
| SI3456340T1 (sl) | 2022-08-31 |
| EP2818181B1 (en) | 2018-10-24 |
| EP3456340A1 (en) | 2019-03-20 |
| ES2908838T3 (es) | 2022-05-04 |
| US20100190700A1 (en) | 2010-07-29 |
| PL3456340T3 (pl) | 2022-08-22 |
| US20190336584A1 (en) | 2019-11-07 |
| US20240082361A1 (en) | 2024-03-14 |
| EP3456340B1 (en) | 2022-02-16 |
| HRP20220346T3 (hr) | 2022-09-02 |
| LT3456340T (lt) | 2022-05-10 |
| US10987407B2 (en) | 2021-04-27 |
| EP4049673A1 (en) | 2022-08-31 |
| ES2499390T3 (es) | 2014-09-29 |
| HUE058307T2 (hu) | 2022-07-28 |
| US10188702B2 (en) | 2019-01-29 |
| EP2120994A4 (en) | 2011-09-28 |
| US20080269130A1 (en) | 2008-10-30 |
| WO2008085982A3 (en) | 2008-11-20 |
| US9616108B2 (en) | 2017-04-11 |
| US20210252110A1 (en) | 2021-08-19 |
| US20180050095A1 (en) | 2018-02-22 |
| EP2120994A2 (en) | 2009-11-25 |
| WO2008085982A2 (en) | 2008-07-17 |
| ES2710948T3 (es) | 2019-04-29 |
| PT3456340T (pt) | 2022-05-25 |
| DK3456340T3 (da) | 2022-03-21 |
| EP2120994B1 (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125273T1 (el) | Ανταγωνιστης υποδοχεα glp-1 για χρηση στη θεραπεια συγγενους υπερινσουλινισμου | |
| CY1120389T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη | |
| DK3989972T3 (da) | Glucagon-lignende peptid-1-receptor-agonister | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
| MX2021001957A (es) | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). | |
| CL2008002097A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2008002521A1 (es) | Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer. | |
| CY1120741T1 (el) | Θεραπεια οζωδους σκληρυνσης | |
| CL2011003085A1 (es) | Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes. | |
| CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| CL2007003202A1 (es) | Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular. | |
| CR10694A (es) | Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso | |
| CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
| CL2008001201A1 (es) | Compuestos derivados de imidazol, triazol y/o piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension o insuficiencia cardiaca. | |
| CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
| CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
| CL2008002159A1 (es) | Compuestos derivados de n-(((1r, 4r)-4-aminociclohexil)metil) sulfonaminas sustituidas con heterociclos, antagonistas del receptor npy y5; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar anorexia y obesidad. | |
| CL2009000171A1 (es) | Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion. | |
| CL2011002697A1 (es) | Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes | |
| CL2009000873A1 (es) | Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b | |
| CL2007002888A1 (es) | Compuestos derivados de n-metansulfonilamino amidas, inhibidores de metaloproteasas de matriz; composicion farmaceutica; y uso para el tratamiento de un trastorno de proliferacion celular. | |
| CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| AR061446A1 (es) | Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico |